ReviewJournal of clinical medicine2024
Fat Matters: Exploring Cancer Risk through the Lens of Computed Tomography and Visceral Adiposity.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Body composition and renal cell carcinoma prognosis in elderly patients: a retrospective cohort study.BMC urology · 2026Article
- Subcutaneous adipose tissue radiodensity as a prognostic marker in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.Contemporary oncology (Poznan, Poland) · 2026Article
- FireVoxel: Interactive Software for Multi-Modality Analysis of Dynamic Medical Images.Journal of imaging informatics in medicine · 2025Review
- Association of body roundness index with prostate cancer: a population-based cross-sectional study using NHANES data.Translational andrology and urology · 2025Article
- Body Composition Measurements as Predictive Variables for Outcomes of Canine Appendicular Osteosarcoma Treated With Stereotactic Body Radiation Therapy.Veterinary and comparative oncology · 2025Article
- High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study.Frontiers in medicine · 2025Article
- Association of visceral obesity indicators with prostate cancer: a cross-sectional study from Xinjiang.Frontiers in oncology · 2025Article
- Percentage of fat in milk consumption and risk of six cancers: a Mendelian randomization study.Translational cancer research · 2024Article
- Mechanisms by which obesity regulates inflammation and anti-tumor immunity in cancer.Biochemical and biophysical research communications · 2024Review
- Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity.Cancers · 2024Review
- Triglyceride-glucose index as a marker for visceral obesity in patients with gastric cancer.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is an established risk factor for cancer. However, conventional measures like body mass index lack precision in assessing specific tissue quantities, particularly of the two primary abdominal fat compartments, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Computed tomography (CT) stands as the gold standard for precisely quantifying diverse tissue types. VAT, distinguished by heightened hormonal and metabolic activity, plays a pivotal role in obesity-related tumor development. Excessive VAT is linked to aberrant secretion of adipokines, proinflammatory cytokines, and growth factors, fostering the carcinogenesis of obesity-related tumors. Accurate quantification of abdominal fat compartments is crucial for understanding VAT as an oncological risk factor. The purpose of the present research is to elucidate the role of CT, performed for staging purposes, in assessing VAT (quantity and distribution) as a critical factor in the oncogenesis of obesity-related tumors. In the field of precision medicine, this work takes on considerable importance, as quantifying VAT in oncological patients becomes fundamental in understanding the influence of VAT on cancer development-the potential "phenotypic expression" of excessive VAT accumulation. Previous studies analyzed in this research showed that VAT is a risk factor for clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, prostate cancer, and hepatocarcinoma recurrence. Further studies will need to quantify VAT in other oncological diseases with specific mutations or gene expressions, in order to investigate the relationship of VAT with tumor genomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.